| abstract |
In certain aspects, the present disclosure can inhibit tumor growth of renal cell carcinoma (RCC) in vivo using a polypeptide comprising a ligand binding portion of the extracellular domain of an activin-like kinase I (ALK1) polypeptide About the insight. In an additional aspect, the present disclosure dramatically illustrates the ability of a polypeptide comprising a ligand binding portion of the extracellular domain of ALK1 to inhibit RCC tumor growth in vivo of a standard therapeutic receptor tyrosine kinase inhibitor. On the insight of increasing |